The FDA is in the process of updating its final counselling on required accuracy of glucose meters and test strips, slightly tweaking a policy put in place in 2016 that tightened the scrutiny of these essential tools for managing diabetes.

While some may curiosity nearly the need or significance of this at a time when day-and-night glucose monitors (CGMs) seem to be supplanting traditional fingerstick meters, the reality is that only a small percentage of PWDs (people with diabetes) are victimization CGM to date; it's unrealistic to think that traditional meters and prove strips will melt anytime soon. That substance strip truth remains critical.

Connected Nov. 29, the FDA issuedupdated guidelines that set the standards for meters used in medical institution settings and personal-use meters. There is a public comment period open through February 2019, after which the agency will review feedback before eventually issuing official, finalized rules.

Those who've been chase this issue over the days May be experiencing déjà vu, from similar discussions and draft guidance published in early 2004 before the final rules came in Oct 2016. That was immense at the time, because accuracy rules hadn't changed in the USA since the 1990s!

Importantly, the new rules issued in 2016 applied to new products only, and did not affect meters and strips already on the market. So while these other tighter accuracy requirements were a positive change, our D-Community had to keep in judgement that lots of less-accurate meters were soundless out there in the hands of people with diabetes. The current updates don't lay out any parvenue ways to police existent meters per se, simply they bash intimate tactics to "close the gap between pre-market and military post-market performance."

"Adjective Changes" to Meter Truth Rules

What was decided in 2016 remains mostly whole — import these novel November 2018 changes don't really improve the practical accuracy of our meters at rest home or in objective settings.

Instead, we're told by the FDA that these newest changes are largely "legal proceeding," addressing how manufacturers must keep track of their processes and the basketball game they must down in acquiring these meters and strips approved for market. The FDA tells these changes came at the particularised asking from industry players, WHO felt the 2016 document required clarification.

"The changes to the both guidances included minor changes," same FDA press officer Stephanie Caccomo. "(Including) clarifying that sponsors should put up justifications for any data exclusions in their method acting comparability and user evaluation, removing specific examples of modifications and lot release criteria examination, and adding comparisons of the candidate device under try conditions to the candidate twist at nominal conditions certainly studies."

Put differently, aspects that don't translate to much for us in the D-Community victimization these products in our own diabetes management all day.

The earlier guidance put off in situ in 2016 happening these two classes of products offered the most meaningful transfer —

For each, the accuracy standards require that blood gelt results fall within a certain percentage of the "reference method" for testing accuracy; they're only allowed to be so far off from the uber-accurate results provided by an in-laboratory glucose test.

FDA tells us they took broad feedback into consideration, to shine a via media that would increase truth without creating besides many roadblocks for industry.

"Based happening feedback received from manufacturers, profit-maximising the truth of these strips too much would increase their costs spell reducing their availability to patients," FDA spokeswoman Stephanie Caccomo said. "Patient feedback indicated that they did not want reduced device usability (from increased testing clock time, increased sample volume, etc.) in ordering to maintain concordant pricing for strips where the accuracy has been increased well."

She added that "this represents a significant accuracy improvement compared to meters marketed eventide 5 years ago," yet FDA believes many of the meters already on the market today should be able meet these improved criteria too.

The specifics of those criteria are as follows:

Clinical Blood Glucose Monitoring Systems (BGMS) –

  • 95% of values must make up within +/-12% for line sugars downstairs Beaver State above 75 mg/decilitre
  • 98% within +/- 15%

By comparison, the preceding rules called for 15% and 20% accuracy across the board. In early 2014, the FDA had proposed tightening the strictest requirement to +/- 10%, but meter manufacturers and nonsubjective healthcare providers objected because it could stop them from either making or obtaining meters affordably. Then the regulators met in the middle at 12%.

The FDA spokeswoman tells us the reason for the discrepancy between the draft and unalterable rules is "to balance the clinical needs in each population with the ability of the manufacturers to produce devices that meet these goals."

Share along Pinterest

Here is a link to the FDA's to the full 43-foliate steering document for clinical meters.

Private-Use Glucose Meters –

  • 95% inside +/- 15% across the measurement range
  • 99% within +/- 20% crosswise the measuring range

Comparatively, the prior rules called for 20% accuracy for most lineage sugar ranges.

As of 2016, personal-use meters likewise need to run "a prominent warning" that their test strips (which allow blood collection in an "open" surround) are not meant for use in clinical settings. This stems from long-erect concerns from both the FDA and Centers for Disease Control (CDC) about the risk of hepatitis B and other roue-borne diseases, and it's the independent conclude the agency split the rules into two different categories.

Here is a link to the FDA's 43-page document for home-use meters.

Other Newly BG Meter Requirements

Manufacturing Process: On the far side vindicatory the accuracy casebook, the FDA also cracked down on manufacturers' lot release methodology — collecting information about manufacturers' sites and the quality of their production. This is  accomplished through "data collection and website inspections," we'atomic number 75 told.

Labeling: Perhaps most importantly, FDA has titled for new labeling information on test strip vials; they moldiness include information almost the lot/production, and a description of the performance (accuracy information) on the outer box label so users can compare one meter to another.

Third gear-Company Tryout Strips: Importantly, the final rules add provisions specific to bump off-brand test strip makers that have come under criticism in past age. While these strips are often inferior-expensive, they haven't been subject to the same requirements for accuracy A the meters — peculiarly when certain brands are made sea, and the Food and Drug Administration isn't able to inspect manufacturing facilities like-minded they do in the US. Instantly, FDA rules say these manufacturers should "see that they are aware of some design changes to the metre because such changes could affect compatibility of the test strip with the cadence." This must equal self-addressed in the 3rd-company party's 510(k) filing, and the FDA also recommends they submit the agreement documentation between the third-party strip maker and meter producer.

"Post-Market Surveillance" of Glucose Meters

In its recent update, the FDA did not include any unused aspects to examine meters and strips in one case they're on the market, aside from the general provender and policies IT already has in situ for inspections and deftness requirements.

But the agency is heedful of the issue, and points to the new test strip lot criteria as a way to address post-market concerns. FDA recommends that, in their 510(k) submissions, manufacturers provide a description of the allot release criteria and a compact of the sampling scheme, which FDA plans to review every bit part of clearance.

"In an effort to familiar the gap between pre-marketplace and post-market performance, and differences between test strip scads, test lot expel criteria should be sufficient to ensure consistent quality of test strips. This testament provide greater consistency across lashing and across manufacturers, and a deterrence for poor post-food market manufacturing decisions," according to spokeswoman Caccomo.

This has been a hot topic in recent years, leading to the emerging Diabetes Technology Society's surveillance program that is gaining steam now.

Submission Is Voluntary?

No dubiousness that new guidelines for tighter truth are a good matter.

The problem is that while medical products essential be FDA approved to come to market in the US, these "guidelines" are non mandatory, but rather "not-cover," i.e. voluntary. This is because the FDA's policies state that its guidance is "not legally binding to a particular course of carry through… (but) nevertheless represents the agency's topper advice on the matter to at issue at the clock time they are rendered" — presumably to protect the agency from getting embroiled in lawsuits.

But… ugh.

Honestly, what's the signal if manufacturers can just opt non to follow these new rules? We can only cross our fingers that market pressure testament incentivize the vendors to comply. Contempt the growing use of CGM and much automated D-technical school, glucose meters and strips remain the "bread and butter" of diabetes direction for the people (as we say), so ensuring accuracy remains important.